Nilotinib is safe and effective for a patient with CML-CP under hemodialysis

Azusa Ikeuchi

Presentation information

Poster Session

Sun. Oct, 14

Poster Session 3-11 CML: Clinical (2)

Sun. Oct 14, 2018 12:40 PM - 1:20 PM Poster1 (Osaka International Convention Center, 3F Event Hall)

Chair: Noriyoshi Iriyama (Hematology & Rheumatology, Nihon University School of Medicine)

[PS3-11-3] Nilotinib is safe and effective for a patient with CML-CP under hemodialysis

Azusa Ikeuchi^1,2, Makiko Horai¹, Hidehiro Itonaga¹, Sachie Tsukada^1,2, Hikaru Sakamoto¹, Hideaki Kitanosono¹, Masataka Taguchi¹, Shinya Sato¹, Koji Ando¹, Yasushi Sawayama¹, Yoshitaka Imaizumi¹, Tomoko Hata¹, Yukiyoshi Moriuchi², Yasushi Miyazaki¹ (1.Department of Hematology, Nagasaki University Hospital, Nagasaki, Japan, 2.Department of Hematology, Sasebo City General Hospital, Sasebo, Japan)

Abstract password authentication.
Password is written on a program and abstract book.